Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/202049
Title: | 2023 GEIS Guidelines for gastrointestinal stromal tumors |
Author: | Serrano, César Martín Broto, Javier Asencio Pascual, José Manuel López Guerrero, José Antonio Rubió Casadevall, Jordi Bagué, Silvia García del Muro, Xavier Fernández Hernández, Juan Ángel Herrero, Luís López Pousa, Antonio Poveda, Andrés Martínez Marín, Virginia GEIS (Grupo Español de Investigación en Sarcomas/Spanish Group for Sarcoma Research) |
Keywords: | Càncer gastrointestinal Cirurgia oncològica Protocols clínics Gastrointestinal cancer Surgical oncology Medical protocols |
Issue Date: | 24-Aug-2023 |
Publisher: | SAGE Publications |
Abstract: | Gastrointestinal stromal tumor (GIST) is the most common malignant neoplasm of mesenchymal origin. GIST spans a wide clinical spectrum that ranges from tumors with essentially no metastatic potential to malignant and life-threatening spread diseases. Gain-of-function mutations in KIT or PDGFRA receptor tyrosine kinases are the crucial drivers of most GISTs, responsible for tumor initiation and evolution throughout the entire course of the disease. The introduction of tyrosine kinase inhibitors targeting these receptors has substantially improved the outcomes in this formerly chemoresistant cancer. As of today, five agents hold regulatory approval for the treatment of GIST: imatinib, sunitinib, regorafenib, ripretinib, and avapritinib. This, in turn, represents a success for a rare neoplasm. During the past two decades, GIST has become a paradigmatic model in cancer for multidisciplinary work, given the disease-specific particularities regarding tumor biology and tumor evolution. Herein, we review currently available evidence for the management of GIST. This clinical practice guideline has been developed by a multidisciplinary expert panel (oncologist, pathologist, surgeon, molecular biologist, radiologist, and representative of patients' advocacy groups) from the Spanish Group for Sarcoma Research, and it is conceived to provide, from a critical perspective, the standard approach for diagnosis, treatment, and follow-up. |
Note: | Reproducció del document publicat a: https://doi.org/10.1177/17588359231192388 |
It is part of: | Therapeutic Advances in Medical Oncology, 2023, vol. 15, p. 17588359231192388 |
URI: | http://hdl.handle.net/2445/202049 |
Related resource: | https://doi.org/10.1177/17588359231192388 |
ISSN: | 1758-8359 |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
serrano-et-al-2023-2023-geis-guidelines-for-gastrointestinal-stromal-tumors.pdf | 530.51 kB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License